# A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

> **NCT03173092** · PHASE4 · TERMINATED · sponsor: **Takeda** · enrollment: 141 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03173092
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-13
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 141 (ACTUAL)
- **Why stopped:** All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met.
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173092, "A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03173092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*